SBIR/STTR Research Award

"Protected" Nanoparticles for an Oral Single-Dose Staphylocaccal Enterotoxin B Vaccine

Award identifier 33ebff819d7323cda1fa5473b209af606b45c771d69e33b1fbd0fe5f06601bd8Awarding agency Department of Defense · Army

Award amount

$69,902

Program and phase

SBIR · Phase I

Award year

1995

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Army
Recipient company
TSRL, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
TP74UMNGJDJ1
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Conventional methods of immunization in general require multiple injections at certain intervals to achieve the required protective immune response. However, this immunization protocol may not always be practical, especially for Army personnel in the field or in remote areas where access to the health care personnel may be difficult. Our program is based on the concept of complete immunization (prime and boosting) with a single oral vaccine dosage form using a time-release capsule - "protected" biodegradable nanoparticles (polyactic-polyglycolic acid) containing staphylococcal enterotoxin B (SEB)-toxoid as a model protein-based antigen. thus, the nanoparticles will be enclosed in a protective time-release capsule known as the PORT System. The capsule is deigned to protect nanoparticles and the encapsulated antigen from both gastric enzymes and acidic pH, and to release the enclosed antigen loaded nanoparticles in a burst in the ileum for optimal uptake by the gut-associated lymphoid tissue to induce an immune response. No other group has investigated this concept of capsule "protected" nanoparticles. Our working hypothesis is that by virtue of our smaller particle size (nanoparticles Vs. previous microparticles), and enteric protection using the PORT System, our oral vaccination approach will prove significantly better than those studied previously. Our goal in the Phase I-SBIR program is to test the feasibility of this concept of oral immunization using SEB-toxoid to achieve an immune response comparable to that of the conventional method of subcutaneous immunization. The long-term objective of our program in the Phase II-SBIR is to further develop our nanoparticle-vaccine system in a time-release capsule for a singel-dose oral SEB vaccine adminsitration in a clinical trial. Nanoparticle-vaccine development will involve the formulation in Phase II-SBIR of various staged booster doses can e simply given orally in a single contact encounter. Ultimately this system may be useful for a combination of vaccines to achieve a long-term protective immune response against vaccine-preventable diseases. Such a system will have importance to US Armed forces in the field,

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

47 SBIR/STTR records share this UEI (1987–2025). Reported award amounts total $35,277,130. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.